Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-EGFRvIII/CD3 bispecific antibody RO7428731

A bispecific antibody directed against both a mutant form of the human epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-EGFRvIII/CD3 bispecific antibody RO7428731 specifically binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and EGFRvIII on EGFRvIII-expressing tumor cells. This crosslinks T-cells and tumor cells, and activates and redirects CTLs to EGFRvIII-expressing tumor cells. This leads to CTL-mediated killing of EGFRvIII-expressing tumor cells. EGFRvIII, a mutant form of EGFR expressed in certain tumor cell types and frequently seen in malignant glioma, plays a key role in tumor cell proliferation and survival.
Synonym:anti-EGFRvIII/anti-CD3 bispecific antibody RO7428731
EGFRvIII x CD3 bispecific antibody RO7428731
Code name:RO 7428731
RO-7428731
RO7428731
Search NCI's Drug Dictionary